📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 19:35
1 analysed today
FollowTelegram
1
Today
151,445
All-time analysed
43,380
Positive
6,733
Negative
92,520
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
Chemcrux Q1 PAT Jumps 466% YoY to ₹0.51 Cr; Revenue Up 33% YoY
Chemcrux Enterprises reported a strong year-on-year recovery for Q1 FY27, with consolidated revenue rising 33% to ₹21.94 Cr from ₹16.50 Cr. Consolidated Net Profit surged to ₹0.51 Cr compared to a low base of ₹0.09 Cr in the same quarter last year. However, performance weakened sequentially (QoQ), with revenue down 9.6% and PAT dropping 72% from ₹1.85 Cr in Q4 FY26. A notable gap exists between standalone PAT (₹1.37 Cr) and consolidated PAT (₹0.51 Cr), indicating losses in its wholly-owned subsidiary, Kalichem Private Limited.
Confidence: HIGH
What changedThe company has scaled its quarterly revenue base above ₹20 Cr consistently over the last three quarters, showing a structural improvement over the ₹16-17 Cr levels seen in early FY26.
Why it mattersFor a micro-cap company with a ₹143 Cr market cap, the ability to maintain higher revenue scales is critical for operating leverage. The widening gap between standalone and consolidated profits highlights a specific execution risk in its subsidiary.
Consolidated Revenue (Q1 FY27): ₹21.94 CrConsolidated PAT (Q1 FY27): ₹0.51 CrYoY Revenue Growth: 33%QoQ Revenue Growth: -9.6%Subsidiary Net Loss (Estimated): ₹0.86 Cr
📅 Short termThe sharp YoY growth in profitability is likely to be viewed positively by the market, although the sequential decline in margins and revenue may limit the upside.
📈 Long termThe company is attempting to scale its specialty chemicals business, but long-term value creation depends on the subsidiary becoming self-sustaining and the successful retention of talent through the new ESOP scheme.
⚠ Risk flags
- Subsidiary losses impacting consolidated bottom line
- Sequential decline in profitability
- High raw material cost sensitivity
Key Highlights
Consolidated Revenue from operations grew 33% YoY to ₹21.94 Cr.
Consolidated PAT increased significantly to ₹0.51 Cr from ₹0.09 Cr in Q1 FY26.
Standalone PAT of ₹1.37 Cr was substantially higher than consolidated PAT, implying a ₹0.86 Cr loss in the subsidiary.
Granted 1,07,700 Employee Stock Options (ESOPs) on May 15, 2026, at an exercise price of ₹10.
Finance costs reduced to ₹0.64 Cr from ₹0.86 Cr on a YoY basis.
👀 What to Watch
Investors should monitor the turnaround progress of the subsidiary Kalichem Private Limited, as its losses are currently dragging down consolidated profitability. Watch for the stabilization of operating margins, which were impacted by a sequential rise in raw material costs relative to revenue.
